


PREPARING FOR PREP: FROM THEORY TO PRACTICE KEY POPULATIONS

Dr Oscar Radebe



ANOVA
HEALTH INSTITUTE



USAID
FROM THE AMERICAN PEOPLE

PrePARING FOR THE END OF HIV

- Until recently there has been exciting new advances in clinical research focusing on HIV prevention for high risk groups .
- *New data on **Prep** studies have given researchers , scientist, politicians, clinicians to respond to the continent's HIV epidemic on a global scale.*



ANOVA
HEALTH INSTITUTE

PrePARING FOR THE END OF HIV

THEORY
Scientific Research

**IMPLEMENTATION
PROCESS**

PRACTICE
Prescribing Prep



ANOVA
HEALTH INSTITUTE

Why do We Need PrEP ?

- 7400 new infections daily
- (600 in SA women daily)
- 15 Million in MLIC need ART
- 5.2 Million on ART by 2010
- For every 1 on ART another 2 infected.



ANOVA
HEALTH INSTITUTE

Key Populations

Key populations are those most likely to be **exposed** to HIV or to **transmit** it.


- People who inject drugs
- Men who have sex with men (MSM)
- Commercial sex workers
- Transgender persons
- Prisoners
- Migrants



ANOVA
HEALTH INSTITUTE

At Risk Populations in South Africa

- Young women 15 to 24 years old
- Young people not attending school; girls who drop out of school
- People from low socio-economic groups
- People living close to national roads and in informal settlements
- Uncircumcised men
- Persons with disabilities and mental disorders
- Sex workers and their clients
- People who abuse alcohol and illegal substances
- Men who have sex with men
- Transgender persons




ANOVA
HEALTH INSTITUTE

Why Prioritise MSM in a Predominantly Heterosexual Epidemic?


MSM are at high risk of HIV transmission and acquisition

- Gay and bisexual men account for **63% of new infections** in the US, and African American men in this group account for more new infections than any other subgroup.
- **Increased HIV risk** compared to general population (OR 3.8 in Africa) [Baral et al 2007]
- Soweto Men's Study MSM HIV prevalence = 20%
 - High rates of unprotected sex
 - High rates of sex with men and with women [Lane 2009]
- JEMS study, South Africa:
MSM HIV prevalence = **43%** [HSRC 2009]



Global Prevalence of HIV in MSM

Gay men and other MSM shoulder a disproportionate burden of the HIV epidemic in virtually every country that reports reliable HIV surveillance data.



Prevalence of HIV in MSM compared with regional adult prevalence reported by UNAIDS 2010¹

Beyrer C, Baral SD, van Griensven, et al, *Global epidemiology of HIV infection in men who have sex with men*, Lancet 2012.



Key Population:

Relatively high HIV / STI Risk

AND

Relatively limited access to health services

HIV Prevalence



**The South African
Marang Men's Project**



ANOVA
HEALTH INSTITUTE

Marang Study Summary

- Largest MSM Surveillance Study in SA
- Some methodological problems
 - Sex workers in Cape Town
 - Students in Durban
 - Jhb possibly the most representative
- High HIV rates and sub-optimal HIV knowledge
- High degrees of bisexuality and concurrency
- Ongoing risky behaviours (e.g. alcohol, low condom use and repeat HIV testing)
- Experience of stigma from health providers



**The South African
Marang Men's Project**



ANOVA
HEALTH INSTITUTE

Risk of HIV Transmission


Type of contact	Transmission Risk (per 10,000)
Receptive anal intercourse	50
Receptive vaginal intercourse	10
Insertive anal intercourse	6.5
Insertive vaginal intercourse	5
Receptive oral intercourse	1
Insertive oral intercourse	0.5

UAI 20 times more risky than for vaginal



ANOVA
HEALTH INSTITUTE

Novel HIV Prevention Intervention Efficacy



ANOVA
HEALTH INSTITUTE

ART-Based PrEP

How are antiretrovirals used?	• Oral pill • Topical gel (microbicide) • Rectal • Vaginal • Injection • Intravaginal ring
How often are the antiretrovirals used?	• Daily • Intermittently • Coitally (before/sex)
How many antiretrovirals are used?	• Combination • Monotherapy
What antiretrovirals are used?	• Truvada • Tenofovir • (Maraviroc)

Post Exposure prophylaxis (PEP)

Treatment as Prevention (TasP)

Combination Prevention with existing and new technologies




ANOVA
HEALTH INSTITUTE

Regulatory Approval for Daily TDF/FTC for Prevention in Host Countries

 TDF/FTC approved for prevention
United States

 Regulatory application filed for a prevention indication for TDF/FTC
Brazil
South Africa
Thailand

 Host countries with no regulatory application filed for prevention
Australia
Ecuador
Kenya
Thailand
Kingdom
Botswana
France
Tanzania
Uganda
Canada
Germany
United



ANOVA
HEALTH INSTITUTE

Four Early Trials Demonstrating PrEP Efficacy in Diverse Geographic and Risk Populations

Study, population	PrEP agent	# of HIV infections		PrEP efficacy (95% CI) publication
		PrEP	placebo	
Partners PrEP Study Heterosexual couples Kenya, Uganda (n=4758)	TDF/FTC	13	52	75% (55-87%)
	TDF	17		67% (44-81%) Baeten et al. N Engl J Med 2012
TDF2 Study Heterosexuals Botswana (n=1219)	TDF/FTC	10	26	62% (16-83%) Thigpen et al. N Engl J Med 2012
Bangkok Tenofovir Study (BTS) IDUs Thailand (n=2413)	TDF	17	33	49% (10-72%) Choopanya et al. Lancet 2013
iPrEx MSM Brazil, Ecuador, Peru, South Africa, Thailand, US (n=2499)	TDF/FTC	36	64	44% (15-63%) Grant et al. N Engl J Med 2010

iPrEx

- Using ART in negative patients on a long term basis to reduce infection risk if they are exposed to the virus
- Seems safe
- High adherence
- Global iPrEx Study



iPrEx *Can a pill prevent HIV?*


Every 11 seconds a person acquires HIV

While current HIV prevention methods help reduce new infections, thousands still become infected with HIV each year. New prevention methods are critical, especially within populations such as men and trans women with their rate of infection not for HIV infection, and in geographic regions such as Africa, Asia and South America, where HIV is so

The world urgently needs
new HIV prevention options

Global iPrEx is the first large efficacy study in MSM to evaluate whether an antiretroviral prevents HIV


2499 MSM & TG: Truvada daily pill vs placebo → 44 % reduction in HIV transmission (95% confidence interval, 15% to 63%; $p = 0.005$)



ANOVA
HEALTH INSTITUTE

iPrEX Study Design & Results

- **High Risk MSM**
- **Randomized 1:1 Daily Oral PREP**
- **FTC/TDF vs Placebo**
- **Followed Monthly on Drug for:**
 - HIV seroconversion
 - Adverse Events
 - Metabolic Effects
 - HBV Flares among HBsAg+
 - Risk Behavior & STIs
 - Adherence
 - If Infected
 - ▶ *Drug Resistance*
 - ▶ *Viral Load*
 - ▶ *CD4+ T Cell Count*






HIV Infections


110 in total (100 incident, 10 at baseline)

**At least on specimen with undetectable RNA
for all incident seroconverters**

Efficacy (MITT) 44% (15-63%)
Infection Numbers: 64 – 36 = 28 averted



PROUD Study, United Kingdom



Outcome: HIV incidence in immediate vs deferred arm



ANOVA
HEALTH INSTITUTE

PROUD Study: Real World PrEP



PROUD

Examining the impact on gay men of
using Pre-Exposure Prophylaxis (PrEP)

MRC

Clinical
Trials
Unit



Public Health
England

PROUD study interim analysis finds pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay men and other men who have sex with men in the UK

Among MSM in the UK, delivery of PrEP (compared to randomization to deferred access to PrEP) *was so effective in preventing HIV* that the deferred arm was discontinued early.

- At baseline, the population was at considerable HIV risk: in the year prior to enrollment 25% had gonorrhea, 10% had syphilis, 40% used PEP, & 74% had recreational drug use



ANOVA
HEALTH INSTITUTE

PROUD Study UK

2800 MSM in UK newly infected
with HIV in 2013

Protection
offered against
HIV by PrEP


86%

- 545 MSM recruited to take Truvada PrEP
- Immediate or delayed initiation with 24 months follow up
- Study stopped early by DSMB as efficacy dictates that continuing would be unethical
- Efficacy =86% (90% CI: 58 – 96%) P-value =0.0002
- Number Needed to Treat =13 (90% CI: 9 – 25)
- HIV incidence amongst gay men in England is much higher than what was thought.
- There was no difference in the rate of STIs other than HIV
- The use of Truvada for PrEP was safe and concerns about resistance are minimal.
- PrEP can be delivered as part as routine HIV reduction package



ANOVA
HEALTH INSTITUTE

IPIRGAY France



- RCT of Truvada versus placebo in 400 recruited high risk MSM
- Sex-based dosing (4 or more doses)
- Relative RR of HIV incidence was 86% (95% CI 40% to 99%, P = 0.002)
- Number needed to treat for 1 year to prevent 1 infection was 18.
- Also stopped early by DSMB because of high efficacy
- Very sexually active
- Did they not by default get almost daily dosing?

86%



ANOVA
HEALTH INSTITUTE

PrEP Works For High-risk People

Subgroup analyses of PrEP trials show that PrEP is effective for those at greatest HIV risk:

- **Heterosexuals (Partners PrEP)** Murnane et al. AIDS 2013
 - *Reporting sex without condoms*
 - *With an STI*
 - *With an HIV+ partner who has a high plasma HIV viral load*
 - *Women <30 years of age*
- **MSM (iPrEx)** Buchbinder et al. Lancet ID 2014; Solomon et al. Clin Infect Dis 2014
 - *Used cocaine*
 - *Had syphilis*
 - *Had anal sex with an HIV+ partner*
- HIV protection estimates for these subgroups were often higher than for the trial population as a whole, because adherence was often greater for persons taking greater risks



ANOVA
HEALTH INSTITUTE

PrEP Safety

- Rates of death, serious adverse events, and laboratory abnormalities (including renal dysfunction) were low and not significantly different between those taking PrEP and those taking placebo
- PrEP was well tolerated
 - Adverse effects occurred in minority of subjects
 - GI adverse effects (e.g., nausea) more common in those receiving PrEP than placebo
 - Occurred in < 10% and primarily during the first month only (PrEP “start up” symptoms)
- PrEP associated with a small change (~ 1%) in bone mineral density but no increased risk of fracture



ANOVA
HEALTH INSTITUTE

Adherence and HIV protection

	% of blood samples with tenofovir detected	HIV protection efficacy in randomized comparison	HIV protection estimate with high adherence
Partners PrEP TDF/FTC arm	81%	75%	90% (tenofovir in blood)
TDF2	79%	62%	78% (prescription refill)
BTS	67%	49%	70% - 84% (tenofovir in blood / pill count)
iPrEx	51%	44%	92% (tenofovir in blood)
FEM-PrEP & VOICE	<30%	No HIV protection	N/A

When adherence was high, HIV protection is consistent and high


Baeten et al N Engl J Med 2012; Thigpen et al N Engl J Med 2012; Choopanya et al Lancet 2013; Grant et al N Engl J Med 2010; Van Damme et al N Engl J Med 2012; Marrazzo et al CROI 2013



ANOVA
HEALTH INSTITUTE

Oral PrEP Adherence

Longitudinal analysis of tenofovir detection in blood samples from persons on PrEP has show that, for those who were taking PrEP, adherence was frequently consistent over time:




Partners PrEP Study, Baeten et al., Lancet ID 2014



ANOVA
HEALTH INSTITUTE

Perfect Adherence is Not Required: iPrEx OLE



Grant et al. Lancet ID 2014



NOVA
HEALTH INSTITUTE

PrEP and ARV Resistance

Resistance from PrEP was very rare, with only a small number who had acute infection at the time they were started on PrEP.

	# of HIV seroconverters assigned PrEP with HIV resistance	
	HIV infected after enrollment	Seronegative acute HIV infection at enrollment
Partners PrEP	0 / 48	2 / 10
iPrEx	0 / 36	2 / 2
TDF2	0 / 10	1 / 1



Resistance = K65R (TDF) or M184V/I (FTC) mutations



ANOVA
HEALTH INSTITUTE

Risk compensation in PrEP clinical trials

In both iPrEx and Partners PrEP, unprotected sex and STIs were less common over time – suggesting synergy of ongoing risk-reduction counseling along with PrEP.



ANOVA
HEALTH INSTITUTE

Prescribing PrEP

- **Risk assessment**
 - PrEP is indicated for those at high HIV risk
- **Eligibility**
 - HIV negative, adequate renal function, HBV testing
- **Follow-up**
 - Prescribe for daily use, periodic HIV testing (3-monthly), counsel about risk-reduction
- **PrEP Cycling**
 - PrEP is not meant to be life-long = for periods of highest risk

Special Communication



HIV Prevention in Clinical Care Settings


2014 Recommendations of the International Antiviral Society-USA Panel

US Public Health Service

PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES - 2014

A CLINICAL PRACTICE GUIDELINE





ANOVA
HEALTH INSTITUTE


Concerns About PrEP Delivery

- Who pays? (DOH keen but not committed)
- Bundling with other services (e.g., FP for women or HAST clinics, doctor or nurse driven)
- Community delivery to create demand and reduce burden on facilities?
- Minimise frequent visits and costs
- Risk screening for targeting (e.g. condomless anal receptive sex for MSM, risk score for serodiscordant couples)
- Adherence monitoring?



ANOVA
HEALTH INSTITUTE

Prep implementation process in South Africa



Health4Men Professional



<http://www.health4men.co.za/health4men-professional/>



ANOVA
HEALTH INSTITUTE

Thank You

Elton John Foundation

PEPFAR / USAID/MAC AIDS FUND

Anova Health Institute

HEALTH
4MEN

top to bottom

Contact:

- Oscar Radebe
- 011 581 5060
- radebe@anovahealth.co.za

www.anovahealth.co.za

www.health4men.co.za

info@health4men.co.za

Slide credits: James McIntyre
Kevin Rebe
Francois Venter
Linda-Gail Bekker